par Dhooge, C.;De Moerloose, Barbara;Laureys, G;Ferster, Alina 
;De Bacquer, Dirk;Philippe, Jonathan ;Leroy, Jules ;Benoît, Yves
Référence Leukemia & lymphoma, 43, 2, page (309-314)
Publication Publié, 2002-02
;De Bacquer, Dirk;Philippe, Jonathan ;Leroy, Jules ;Benoît, YvesRéférence Leukemia & lymphoma, 43, 2, page (309-314)
Publication Publié, 2002-02
Article révisé par les pairs
| Résumé : | The improved cure rate in childhood ALL may be attributed largely to the effective multidrug regimens currently applied in well-designed clinical trials. However, in a minority of patients with ALL, chemotherapy failure remains a leading cause of cancer related death, most probably due to cellular drug resistance. The better-known mechanism of such resistance is mediated by P-glycoprotein (P-gp). In a long term prospective study (mean time of follow-up: 65 months) the multidrug efflux pump P-gp was examined immunocytochemically in leukemic cells of 102 protocol-treated children with de novo acute lymphoblastic leukemia (ALL) and of 37 children with relapsed ALL. Fourteen percent expressed P-gp at initial diagnosis and 35% were P-gp positive at relapse. The patients being P-gp positive at initial diagnosis had a higher rate of leukemic relapse than the P-gp negative patients (P = 0.02). In the relapsing patients, those who were P-gp positive had a 2.18-fold greater risk for leukemic death than those who were P-gp negative. Paired analysis on diagnostic and relapsed samples from 20 patients did not support the hypothesis of P-gp mediated expression being a chemotherapy induced phenomenon. The cumulative event free survival for de novo ALL patients was significantly higher in the P-gp negative patient group. Multivariate analysis showed that P-gp expression is independent of other known risk factors. In conclusion we strongly advise that tests for P-gp in leukemic blasts should be conducted for every child with ALL, since this parameter selects a subgroup of patients with increased risk for leukemic relapse. |
